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Ventricular septal defects (VSDs) are the most commonly occurring congenital heart defect. They are
regularly associated with complex syndromes, including DiGeorge syndrome and Holt–Oram syndrome,
which are characterised by haploinsufﬁciency for the T-box transcription factors TBX1 and TBX5,
respectively. The histone acetyltransferase monocytic leukaemia zinc ﬁnger protein, MOZ (MYST3/
KAT6A), is required for the expression of the Tbx1 and Tbx5 genes. Homozygous loss of MOZ results in
DiGeorge syndrome-like defects including VSD. The Moz gene is expressed in the ectodermal, meso-
dermal and endodermal aspects of the developing pharyngeal apparatus and heart; however it is unclear
in which of these tissues MOZ is required for heart development. The role of MOZ in the activation of
Tbx1 would suggest a requirement for MOZ in the mesoderm, because deletion of Tbx1 in the mesoderm
causes VSDs. Here, we investigated the tissue-speciﬁc requirements for MOZ in the mesoderm. We
demonstrate that Mesp1-cre-mediated deletion of Moz results in high penetrance of VSDs and overriding
aorta and a signiﬁcant decrease in MOZ-dependant Tbx1 and Tbx5 expression. Together, our data suggest
that the molecular pathogenesis of VSDs in Moz germline mutant mice is due to loss of MOZ-dependant
activation of mesodermal Tbx1 and Tbx5 expression.
& 2015 Elsevier Inc. All rights reserved.Introduction
Congenital heart disease (CHD) accounts for approximately
one-third of all congenital disorders (Dolk et al., 2011). Ventricular
septal defects (VSDs) are the most common CHD at 2.62 per
1000 births (van der Linde et al., 2011). VSDs can occur in isolation
or as part of complex developmental syndromes, such as DiGeorge
syndrome (velo-cardio-facial/22q11.2 deletion syndrome) and
Holt–Oram syndrome.
DiGeorge syndrome is caused by a heterozygous microdeletion
at chromosomal region 22q11.2 (de la Chapelle et al., 1981; Driscoll
et al., 1992a, 1992b; Scambler et al., 1991). The T-box transcription
factor encoding gene, TBX1, is central to the deletion interval and in
rare cases DiGeorge syndrome is caused by heterozygous mutations
in TBX1 alone (Yagi et al., 2003; Paylor et al., 2006; Torres-Juan et al.,
2007; Zweier et al., 2007). Mice heterozygous for Tbx1 display a
number of characteristic DiGeorge syndrome (DGS)-like anomalies
(Jerome and Papaioannou, 2001; Lindsay et al., 2001; Merscherute of Medical Research, 1G
stralia.
as),
nior authorship.et al., 2001). Major clinical features of the syndrome include con-
otruncal cardiac anomaly and craniofacial defects (Botto et al., 2003;
Kobrynski and Sullivan, 2007). Approximately 80% of DGS patients
are born with CHDs, including VSDs and malformations of the
cardiac outﬂow tract (OFT) (McDonald-McGinn and Sullivan, 2011).
Holt–Oram syndrome is caused by haploinsufﬁciency of
another T-box factor gene, TBX5 (Basson et al., 1997; Li et al., 1997).
Patients display upper limb abnormalities and more than 85%
present with CHDs, including atrial and ventricular septal defects
and OFT malformations. Tbx5 heterozygous mice model Holt–
Oram syndrome (Bruneau et al., 2001; Koshiba-Takeuchi et al.,
2006; Mori et al., 2006).
We have previously reported that the chromatin modiﬁer
monocytic leukaemia zinc ﬁnger protein (MOZ/MYST3/KAT6A) is
essential for normal activation of the Tbx1 and Tbx5 genes in vivo
(Voss et al., 2012b). MOZ is a member of the MYST family of his-
tone acetyltransferases (Thomas and Voss, 2007; Voss and Tho-
mas, 2009) and was ﬁrst identiﬁed in chromosomal translocations
causing acute myeloid leukaemia (Borrow et al., 1996). MOZ is
required for histone 3 lysine 9 acetylation (H3K9ac) at Hox genes
and lack of MOZ results in inadequate Hox gene expression and an
extensive anterior homeotic transformation (Voss et al., 2009).
Importantly, Moz homozygous mutant mice phenocopy DiGeorge
syndrome. They display craniofacial defects and hyperplastic or
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aortic arch defects (74% penetrance) and VSDs (95% penetrance;
Voss et al., 2012b). In this context, MOZ is required for H3K9ac and
expression of the Tbx1 and Tbx5 genes and transgenic over-
expression of Tbx1 rescues the VSDs in homozygous Moz mutant
mice (Voss et al., 2012b). Here, we focus on the mesoderm-speciﬁc
role of MOZ in heart and pharyngeal apparatus development.
Development of the structures affected in DiGeorge syndrome
is known to be exquisitely sensitive to time- and tissue-speciﬁc
expression of Tbx1 (Aggarwal et al., 2010; Liao et al., 2004; Zhang
and Baldini, 2008; Zhang et al., 2005, 2006). Tbx1 is expressed in
the ectoderm, endoderm and mesoderm, but not in neural crest
(Chapman et al., 1996). The VSDs caused by Tbx1 mutation have
been traced to the mesodermal expression domain (Zhang et al.,
2006). Using mesoderm posterior 1 (Mesp1-cre) promoter driven
cre-recombinase to delete the Mozlox conditional mutant allele, we
determined the tissue-speciﬁc requirements for MOZ within the
mesoderm, where both Tbx1 and Tbx5 are expressed. We found
that cardiac septum development requires mesodermal MOZ and
that expression of both Tbx1 and Tbx5 is decreased afterMesp1-cre
deletion of Moz.Results and discussion
The Mozlox allele (Voss et al., 2009) incorporates loxP sites
ﬂanking exons 3–7, deletion of which results in complete loss of
function. The Mesp1-cre knock-in allele (Mesp1-creKI) is active in
the anterior mesoderm from E6.5 onwards (Saga et al., 1999;
Fig. 1A). The deletion efﬁciency of Mesp1-creKI was quantiﬁed by
assessing the level of residual Mozlox allele in the heart. The
functional Mozlox allele was reduced to approximately 20% of the
level of undeleted littermate controls (Fig. 1B). Though these non-
deleted cells likely included some Mesp1-negative cells present inFig. 1. Mesp1-cre deletion of Moz causes lethality between E18.5 and sexual maturity. (A
Mesp1-cre-expressing cells (blue) in the anterior mesoderm, after Saga et al. (2000) an
quantiﬁcation of Mesp1-cre-mediated deletion of the Mozlox allele in mesoderm-rich he
relative to Mozlox/lox;Mesp1-creþ /þ tissues. Data are displayed as mean7standard error
distribution among offspring from Mozlox/lox;Mesp1-creþ /KI x Mozlox/lox;Mesp1-creþ /þ cro
E18.5 and PN7 inferred based on percentage of Mozlox/lox;Mesp1-creþ /KI animals at boththe heart (Kitajima et al., 2006), cells which escaped recombina-
tion of Mozlox alleles may also have contributed to the residual 20%
Mozlox signal in Mozlox/lox;Mesp1-creþ /KI hearts.
Mesoderm-deleted Mozlox/lox;Mesp1-creþ /KI animals crossed with
Mozlox/lox mice without the Mesp1-creKI allele (Mozlox/lox;Mesp1þ /þ)
produced offspring of both parental genotypes. However, the Moz
mesoderm-deleted animals were signiﬁcantly and progressively
underrepresented compared to the expected 1:1 ratio (Fig. 1C),
showing that mesoderm deletion ofMoz resulted in lethality over an
extended period of time. Nevertheless, approximately 40% of the
Mozlox/lox;Mesp1-creþ /KI animals survived and were outwardly nor-
mal and fertile.
Approximately two-thirds of the losses ofMozlox/lox;Mesp1-creþ /KI
animals occurred before postnatal day (PN)7, whereas the remaining
deaths (or terminal disease¼ethical endpoint) occurred between
weaning and sexual maturity at 6 weeks of age (Fig. 1D). The latter
were associated with respiratory distress, weight loss and a hunched
posture. Together our data suggest that mesoderm-speciﬁc deletion
of Moz causes lethality during three distinct periods, (a) during
foetal development before E18.5 (26%), (b) between E18.5 and PN7
(14%) and (c) between weaning and sexual maturity (19%),
resulting in a total loss of 60% of all anterior mesoderm Moz
deleted animals.
Moz germline mutation causes foetal or perinatal death. Moz–/–
DGS-like anomalies include cleft palate and severe cardiovascular
abnormalities. We therefore examined litters ofMozlox/lox;Mesp1-creþ /þ
females crossed withMozlox/lox;Mesp1-creþ /KImales for DGS-like defects
at E18.5.
The majority of Moz mesoderm-deleted pups (23/25) had aortic
arches indistinguishable from littermate controls (34/34; Fig. 2A–B′).
However, two Mozlox/lox;Mesp1-creþ /KI pups (8%) exhibited aortic
arch defects, namely one case of right-sided descending aorta with
aberrant origin of the right subclavian artery from the pulmonary
trunk (Fig. 2C,C′) and one instance of right-sided aortic arch. These) Schematic representation of the Mesp1 expression pattern (purple) and lineage of
d Saga et al. (1999). Extraembryonic mesoderm domain stippled (E7.5). (B) Q-PCR
art tissue at E9.5, E10.5 and E12.5, normalised to the reference gene Hsp90ab1 and
of the mean (s.e.m.) and were analysed by unpaired two-sided t-test. (C) Genotype
sses. (D) Survival curve of Moz Mesp1-cre-deleted mice and controls. *data between
of those ages.
Fig. 2. Aortic arch defects in E18.5 Moz mesoderm-deleted mutant pups. (A–C) Macroscopic view of the great vessels at E18.5 and (A′–C′) traced. Note the mispatterned
aortic arch in a subset ofMozlox/lox;Mesp1-creþ /KI pups (C,C′) compared with unaffectedMozlox/lox;Mesp1-creþ /KI pups (B,B′) andMozlox/lox;Mesp1-creþ /þ littermate controls (A,
A′). (D–H) Thymus (D–F) and ventral view of the palate after removal of the lower jaw (G,H) in genotypes indicated above. Representative images are shown. AA, ascending
aorta; DA*, abnormal ductus arteriosus; DeA, descending aorta; HP, SP hard and soft palate; LCCA, RCCA left and right common carotid artery; LL, RL, left and right lobe of the
thymus; LSCA, RSCA left and right subclavian artery; aRSCA*, aberrant origin of the right subclavian artery; PT, pulmonary trunk; rDeA*, descending aorta abnormally
descending on the right. Scale bar¼1150 mm (A–C), 1100 mm (D–F) and 1660 mm (G,H).
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either the left (right-sided aortic arch) or right (aberrant origin of the
right subclavian artery) fourth pharyngeal arch artery (Lindsay and
Baldini, 2001), a hallmark of Tbx1-dependant DGS-like anomalies of
the aortic arch (Jerome and Papaioannou, 2001; Lindsay et al., 2001;
Merscher et al., 2001; Randall et al., 2009). Whilst aortic arch defects
would contribute to loss of Moz mesoderm-deleted animals soon
after birth, they do not account for loss of 60% of these animals by
10 weeks of age. Examination of the thymus and palate revealed no
DGS-like abnormalities of these structures in either genotype
(Fig. 2D–H).
Given the high incidence of VSDs in Moz germline mutant ani-
mals (95%), we examined haematoxylin and eosin (H&E)-stained
serial sections of E18.5 hearts. 21 of 22 Mozlox/lox;Mesp1-creþ /KI
hearts displayed VSDs, compared with none in the control hearts(0/4; Mozþ /þ;Mesp1-creþ /KI; Fig. 3A,E), suggesting that the VSDs
observed in Moz germline deleted animals are caused by loss of
mesodermal MOZ.
Interestingly, the VSDs could be categorised as mild (a very small
passage between the left and right ventricles, 2/22; Fig. 3B,F),
moderate (a slightly larger disruption of the septum, 7/22; Fig. 3C,G)
or severe (comprising an overriding aorta positioned above a major
VSD, 12/22; Fig. 3D,H). One Moz mesoderm-deleted pup had no
discernable VSD (summarised in Fig. 3I). Furthermore, three Moz
mesoderm-deleted mutants displayed atrioventricular septal defects
(AVSD; Fig. 3J–L).
The VSD data suggest an explanation for the time course of
death observed for the Mozlox/lox;Mesp1-creþ /KI animals. A severe
VSD with overriding aorta likely causes lethality, as the heart is
unable to separate blood ﬂow and thus oxygen supply to the
Fig. 3. Cardiac septal defects in E18.5 Moz mesoderm-deleted mutant pups. H&E stained sections of hearts of Mozþ /þ;Mesp1-creþ /KI (A–D,J) and Mozlox/lox;Mesp1-creþ /KI
(E–H,K) E18.5 pups, overview (A,E) and higher magniﬁcation images (B–D,F–H,J,K). VSDs occurred as mild (arrows in F), moderate (arrowhead in G) or severe with overriding
aorta (asterisk in E,H) inMozlox/lox;Mesp1-creþ /KI, but not in control, mice. (I) Summary of the incidence and severity of VSDs. (J,K) An AVSD (hash in K) was observed in some
Mozlox/lox;Mesp1-creþ /KI animals and never in the controls. (L) Summary of the incidence of AVSDs. Ao, aorta; DMP, dorsal mesenchymal protrusion; LA, RA, left and right
atrium; LV, RV, left and right ventricle; VS, ventricular septum. Scale bar¼580 mm (A,E) and 300 mm (B–D,F–H,J,K).
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correspond: 55% of E18.5 pups had severe VSDs and 59% of Moz
mesoderm deleted animals were lost, suggesting that most ani-
mals with moderate and mild VSDs survived.
Chromatin-mediated mechanisms have been shown to be of
great importance in the development of the cardiovascular systems
(reviewed in Vallaster et al. (2012)). Both TBX1 and TBX5 aid in
recruiting chromatin modiﬁers to their target genes to enable gene
expression (Miller et al., 2008; Stoller et al., 2010). Interestingly,
TBX5 also interacts directly with another MYST family histone
acetyltransferase, TIP60 (Barron et al., 2005). Previously, we have
identiﬁed Tbx1 and Tbx5 as direct targets of the histone acetyl-
transferase MOZ during embryonic development (Voss et al.,
2012b). Given that the syndromes caused by haploinsufﬁciency of
both these transcription factors involve VSDs, we hypothesised that
the VSDs observed in Moz mesoderm-deleted animals may be due
to compromise of MOZ-dependant, mesoderm-speciﬁc expression
of Tbx1 and Tbx5.Previous analysis of the relationship between Moz and Tbx1
and Tbx5 demonstrated that, in the absence of MOZ, H3K9ac at
these genes and their mRNA levels were dramatically affected at
E9.5 and E10.5 (Voss et al., 2012b). We therefore examined the
expression of Tbx1 and Tbx5 by whole-mount in situ hybridisation
at E9.5 and E10.5 and RT-qPCR analysis at E10.5 in Moz;Mesp1-cre-
deleted embryos and controls.
RNA/RNA in situ hybridisation revealed a generalised decrease
in Tbx1 mRNA signal in Mozlox/lox;Mesp1-creþ /KI embryos com-
pared to control embryos at E9.5 (Fig. 4A,B) and E10.5 (Fig. 4E,F,E′,F
′). Germline deletion of Moz results in depletion of Tbx1 mRNA to
an average of 50–60% wild type levels by RT-qPCR (Voss et al.,
2012b). Here we determined that mesoderm-speciﬁc deletion of
Moz reduced Tbx1 to 55% of control levels by RT-qPCR (Fig. 4I),
suggesting that the requirement for MOZ in regulating Tbx1
expression is primarily or exclusively dependant on mesodermal
expression of Moz.
Tbx5 expression in Mozlox/lox;Mesp1-creþ /KI E9.5 embryos was
only slightly compromised compared to control embryos in the
Fig. 4. Decreased gene expression inMozmesoderm-deleted embryos and direct binding of MOZ to the Tbx1 and Tbx5 locus. Whole-mount in situ hybridisation of E9.5 (A–D)
or E10.5 (E–H and sectioned in E′–H′) embryos for Tbx1 (A,B,E,F,E′,F′) and Tbx5 mRNA (C,D,G,H,G′,H′). Tbx1 mRNA signal is broadly decreased in Moz mesoderm-deleted
embryos at both time points (B,F,F′ compared with A,E,E′ arrow in F′ indicates decreased Tbx1 signal in paraxial mesoderm compared to E′). Note that this technique was not
sensitive enough to detect Tbx1 expression in the secondary heart ﬁeld. Tbx5 mRNA appears reduced in the DMP (arrow in D,C) but unaffected in the forelimb bud
(arrowheads in C,D) at E9.5. Colour reaction was terminated prior to full development of the signal to reveal subtle changes in the DMP. At E10.5, Tbx5 signal is substantially
depleted in the left ventricle (arrows in G,H), right atrium, second heart ﬁeld and nascent pulmonary mesoderm (RA and arrow, respectively, in G′,H′) and only moderately
affected in the forelimb (arrowhead in G,H). (I–J) RT-qPCR analysis of mRNA levels of Tbx1 and Tbx5 (I) and other genes important for heart and cardiac septum development
(J) in E10.5 embryos. Legend in J also applies to I. (K,L) Detection of MOZ-V5 at Tbx1 and Tbx5 loci in vivo. Data are presented as enrichment over signal from V5-negative
(Mozþ /þ) tissue after normalisation to an internal IP intergenic control locus (K) or input (L). ‘_1’ and ‘_2’ indicates 1 and 0.49 kb upstream of the transcription start site (TSS)
and 0.77 and 0.28 kb upstream the TSS, for Tbx1 and Tbx5, respectively. Note that the low enrichment at Tbx1 likely reﬂects the small, MOZ-V5-bound Tbx1 expression
domain within the pharyngeal arches compared to the MOZ-V5-bound Tbx5 expression domain throughout the heart. Scale bar¼380 mm (A–D,G,H), 500 mm (E,F) and
200 mm (E′–H′). Data are displayed as mean7s.e.m. and were analysed by unpaired two-sided t-test (RT-qPCR) or 2-way ANOVA with genotype and genomic site within
gene locus as the two independent factors (ChIP-qPCR); *po0.05; **po0.01; ***po0.001; n.s., not signiﬁcant.
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(Fig. 4C,D). However, one day later, at E10.5, there was a dramatic
reduction in signal in the left ventricle and right atrium of
Mozlox/lox;Mesp1-creþ /KI embryos (Fig. 4G,H,G',H'), whereas Tbx5
mRNA signal in the forelimb was only moderately reduced(Fig. 4H,G). RTqPCR showed Tbx5 mRNA levels at 75% control
levels in Mozlox/lox;Mesp1-creþ /KI embryos (Fig. 4I). Given that
MESP1 is thought to directly regulate Tbx5 (Christoforou et al.,
2013; Lindsley et al., 2008), we included the Mozlox/þ;
Mesp1-creþ /KI genotype to control for Mesp1 heterozygosity in the
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Mesp1 double heterozygous animals displayed no compromise in
Tbx5 expression (Fig. 4I), suggesting that the decrease in Tbx5
mRNA levels in Mozlox/lox;Mesp1-creþ /KI embryos is primarily due
to homozygous loss of mesodermal Moz expression. Our previous
chromatin immunoprecipitation (ChIP) results in germline deleted
Moz–/– embryos (Voss et al., 2012b) suggest that the reduction in
Tbx1 and Tbx5 mRNA levels in Moz mesoderm-deleted embryos
would be accompanied loss of MOZ-dependant H3K9ac at the Tbx1
and Tbx5 loci.
In addition to Tbx1 and Tbx5, we examined the expression of
the Pitx2, Gata4 and Nkx2.5 genes encoding transcription factors
important for heart development, which, when mutated, result in
cardiac septal defects in mice (Gittenberger-de Groot et al., 2014;
Lin et al., 2012). Mutations in PITX2, GATA4 and NKX2.5 have been
implicated in the pathogenesis of cardiac septal defects in humans
(Gittenberger-de Groot et al., 2014; Lin et al., 2012). In addition, we
examined Frzb mRNA, which encodes a secreted antagonist of
WNT signalling that is required for atrioventricular cardiac cushion
development in the chicken (Person et al., 2005). Furthermore,
mutation of FRZB has been associated with one case of atrioven-
tricular septal defect in humans (Ackerman et al., 2012). Interest-
ingly, murine Frzb expression decreases in the absence of Tbx1
in vivo (Liao et al., 2008) and is upregulated when Tbx5 is over-
expressed in mouse cardio ﬁbroblasts (Zhou et al., 2012). Pitx2 is
directly regulated by TBX1 in the secondary heart ﬁeld (Now-
otschin et al., 2006). In the absence of mesodermal Moz expres-
sion, Pitx2, Gata4 and Frzb mRNA levels were signiﬁcantly reduced
compared to controls (Fig. 4J). In contrast, expression of Nkx2.5
was not changed, demonstrating that the effect of loss of meso-
dermal MOZ has speciﬁc, rather than global, effects on genes
important for heart and cardiac septal development.
We previously reported the presence of the MOZ complex at
the Tbx1 and Tbx5 loci, by performing ChIP using an antibody
against ING5, a member of the MOZ complex, in the absence of a
ChIP-grade antibody against MOZ. We have generated a knock-in
mouse strain with a Moz allele that encodes full-length MOZ with
a triple FLAG–V5–biotinylation signal sequence tag (FLAG–V5–BIO)
fused to the carboxy-terminus (MOZ-V5). Unlike the Moz–/– mice,
MozV5/V5 animals are viable and healthy, indicating that the MOZ-
V5 fusion protein is functional. Anti-V5 ChIP was performed on
Tbx1-enriched (microdissected ﬁrst and second pharyngeal arches;
Fig. 4K) and Tbx5-enriched tissue (sets of 3 pooled microdissected
hearts; Fig. 4L) from E10.5MozV5/V5 andMozþ /þ embryos. MOZ-V5
enrichment at both loci over background in Mozþ /þ tissues was
observed, providing evidence that the MOZ protein directly
occupies the Tbx1 and Tbx5 locus.
Our previous data have shown that, despite an 50% decrease
in Tbx1 expression levels, germline-deleted Moz mutants display
much higher penetrance of DGS-like defects than Tbx1 hetero-
zygous animals, including 74% aortic arch defects compared to
11–38% in animals with various Tbx1 heterozygous alleles (sum-
marised in Voss et al. (2012b)). This suggests that other MOZ-
dependant genes in addition to Tbx1 contribute to the DGS-like
anomalies in Moz germline-deleted mutants. For example, Tbx5
down-regulation is likely to contribute to the high incidence of
VSDs. Moreover, transgenic overexpression of Tbx1 rescued the
heart septal defects in germline Moz mutants, but not other DGS-
like defects (Voss et al., 2012b). Interestingly, the low penetrance
of aortic arch defects (8%) in Mozlox/lox;Mesp1-creþ /KI models Tbx1
heterozygosity (11–38% penetrant) much more closely than Moz
germline deletion (74% penetrant) does, suggesting that the TBX1-
independent mechanisms that contribute to the Moz germline
mutant aortic arch phenotype may occur in tissues other than the
mesoderm.Here we show that normal expression of the Tbx1 and Tbx5
genes is dependant on the histone acetyltransferase, MOZ, in the
mesoderm. Compromise of this activation, by mesoderm-speciﬁc
deletion of Moz, results in a high incidence of DGS-like VSDs.Materials and methods
All animal experiments were approved by the Walter and Eliza
Hall Institute Animal Ethics Committee and conducted in accor-
dance with the Australian code of practise for the care and use of
animals for scientiﬁc purposes.
Mozlox (Voss et al., 2009), Mesp1-creKI (Saga et al., 1999) and
MozV5 mice were maintained on the C57BL/6 background. The
MozV5 allele was generated by inserting a FLAG–V5–BIO triple tag
(Schwickert et al., 2014; Soler et al., 2010) into the endogenous Moz
locus at the carboxy-terminus (MOZ-V5) using homologous
recombination of a Moz-containing BAC in Escherichia coli, followed
by targeting of the Moz locus in embryonic stem cells and germline
chimera production. Noon of the day a vaginal plug was observed
was considered embryonic day 0.5 (E0.5). Embryos and pups were
collected at E9.5, E10.5, E12.5 and E18.5 and animals suffering
respiratory distress or other illnesses were euthanised to minimise
suffering (ethical endpoint in accordance with code of practise).
Genomic DNA was extracted from E9.5, E10.5 and E12.5 isolated
hearts to quantify the efﬁciency of conversion of the Mozlox allele to
the Moz– deleted allele. qPCR was performed using the following
primers targeted to Mozlox: 5′-ACCATGTGAGCACATGCATGC-3′; 5′-
ATAGGAACTTCATCAGTCAGGTA-3′. Hsp90ab1 was used as a reference
gene to control for variation in genomic DNA input using the primers:
5′-AATTGACATCATCCCCAACC-3′, 5′-TCGTGCCAGACTTAGCAATG-3′. For
mRNA analysis, E10.5 embryos were collected and their forelimb buds
removed, to quantify more accurately the Tbx5 expression domains
relevant to heart development. RT-qPCR primers against Tbx1, Tbx5,
Pitx2, Gata4 and Nkx2-5 as well as the housekeeping control genes
HSP90ab1 and Pgk1 and ChIP-qPCR primers Tbx1_1, Tbx1_2, Tbx5_1
and Tbx5_2 were previously described (Voss et al., 2012b). The fol-
lowing RT-qPCR primers were also used: Frzb, 5′-GGCTATGAA-
GACGAGGAACG-3′ and 5′-CCAAGGTGTCGGAGTTTCAT-3′ Psmb2, 5′-
GAGGGCAGTGGAGCTTCTTA-3′ and 5′-AGGTGGGCAGATTCAAGATG-3′
and MOZ-V5-unbound intergenic control for ChIP-qPCR, 5′-TGACA-
GAGGCTTGGAGTCCT-3′ and 5′-TCCTCTTCTGGTTCCCCTTT-3′. SYBR-
green technology (SensiMix™, Bioline, UK) on the LightCycler 480
(Roche, Switzerland) was used for qPCR, following cDNA preparation
with Superscript IIIs (Life Technologies, USA) for RT-qPCR according to
manufacturer's instructions. ChIP was performed as previously
described (Voss et al., 2012a) with the following modiﬁcations:
microdissected tissue was cross-linked for 10 min in 1% paraf-
ormaldehyde. Chromatin was sheared using the S220 Covaris soni-
cator (105 peak incident power; duty factor 7; 200 cycles/burst; 40 s;
USA) and incubated in 1 ml ChIP dilution buffer (Voss et al., 2012a)
with 20 ml of anti-V5-conjugated agarose beads (Sigma, A7345) pre-
cleared with 0.2% BSA in ChIP dilution buffer. The immunoprecipitated
DNA was puriﬁed using ChIP DNA Clean & Concentrator kit (Zymo
Research, D5205) according to manufacturer's instructions, before
quantiﬁcation by qPCR.
Thymus and aortic arch defects were examined at E18.5 via
microdissection and scored prior to genotyping. Palates were
examined post-ﬁxation in Bouin's ﬁxative. Hearts were collected
and ﬁxed in 4% paraformaldehyde overnight before serial sec-
tioning and staining with H&E.
Whole-mount in situ hybridisation was carried out as previously
described (Thomas et al., 2007) with antisense probes to Tbx1 and
Tbx5 kindly provided by V.E. Papaiaonnou (Chapman et al., 1996).
Statistical analyses were conducted using Stata/IC 10.0 (Stata
Corporation, USA). Frequencies of expected and observed genotypes
H.K. Vanyai et al. / Developmental Biology 403 (2015) 22–2928at E18.5, weaning and 10 weeks of age were examined by linear
regression with Moz gene deletion status and age as two indepen-
dent variables. The time course of deaths observed in Moz deleted
animals after PN7 was examined in a Kaplan–Meier survivor func-
tion and incidence of deaths between genotypes were assessed by
Pearson's chi-square test.Author contributions
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